This study is investigating darbepoetin alfa for the treatment of anemia in patients with
non-myeloid cancers who are receiving chemotherapy. Darbepoetin alfa is a recombinant protein
that stimulates the production of red blood cells. In this study, darbepoetin alfa will be
administered as either an injection under the skin (subcutaneously) or directly into a vein
(intravenously).